Corporate Profile

CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs specifically designed to address limitations of current therapies in selected established markets.  We have developed a broad portfolio of 12 product candidates utilizing our drug formulation technology using Captisol^® cyclodextrins.  Captisol cyclodextrins are a patent protected, specifically modified family of cyclodextrins designed to improve solubility, stability, bioavailability, safety and/or dosing of a number of active pharmaceutical ingredients, or APIs.  In order to maximize our internal resources, experience and technology, we are focusing on the development and commercialization of product candidates for use in the acute care hospital setting. For those product candidates that likely will entail more extensive development and commercialization efforts, we partner with established pharmaceutical or specialty pharmaceutical companies.  We also outlicense our Captisol technology to third parties for use in the development of their own products.

Historically, we have focused on the outlicense of our Captisol technology to established pharmaceutical companies for the application to, and improvement of, product candidates in their pipelines. Our technology has been validated by the launch of four Captisol-Enabled products commercialized by two of our outlicensees, Pfizer and BMS. We originally focused on this strategy in order to accelerate the commercialization of our Captisol technology and create cash flow for our company. In doing so, we have created a profitable specialty pharmaceuticals business, which has allowed us to expand our strategy to capitalize on the growth opportunities and business lines enabled by Captisol.  More recently, we have been focusing on the development of our retained product candidates for use in the acute care hospital setting, as well as our partner product candidates which we have collaborated with, outlicensed or intend to outlicense to established pharmaceutical companies for development and commercialization.

CAPTISOL and Captisol-Enabled are registered trademarks of CyDex Pharmaceuticals, Inc.